NASDAQ$CGEM
Cullinan Oncology Inc · Q2 2021 earnings
Q2 2021 earnings · · Investor relations
Briefing
Announced second quarter 2021 financial results and provided a corporate update.
Cullinan Oncology reported a strong cash position of $456.3 million as of June 30, 2021, and highlighted the IND clearance of two immuno-oncology pipeline programs, Cullinan MICA and Cullinan Florentine. Interim data from the Cullinan Pearl trial showed a disease control rate of 92% in the 100mg dose cohort.
- Cullinan Pearl data showed increased disease control rate of 92% in the 100mg dose cohort.
- IND clearance was received for two immuno-oncology pipeline programs: Cullinan MICA and Cullinan Florentine.
- Clinical trial starts for Cullinan MICA and Cullinan Florentine are expected in 2H 2021.
- Cash and investments totaled $456.3 million as of June 30, 2021.
Headline financials
Revenue & EPS history
Cullinan Oncology · Revenue · Quarterly
$18.9M
Forward guidance
Cullinan Oncology expects to provide updated preclinical data on Cullinan Amber and a clinical and regulatory update on Cullinan Pearl in the fourth quarter.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 20 quarterly earnings reports · overlaid with Q2 2021
+0.5%
Avg return
Earnings day
-0.2%
Avg return
5 days after
-2.1%
Avg return
30 days after
55%
11 / 20 earnings
Positive
+13.5%
Q1 2022
Best reaction
-10.8%
Q2 2025
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | -2.6% | +7.7% | -10.0% | |
| Q3 2025 | +0.8% | +6.7% | +44.9% | |
| Q2 2025 | -10.8% | -7.7% | -11.3% | |
| Q1 2025 | +2.3% | +1.3% | +5.8% | |
| Q4 2024 | +1.9% | -3.8% | -5.1% | |
| Q3 2024 | -2.8% | -2.8% | -20.8% | |
| Q1 2024 | -9.7% | -9.1% | -28.4% | |
| Q4 2023 | -6.2% | -8.7% | -1.8% | |
| Q3 2023 | -2.7% | -11.1% | -17.7% | |
| Q2 2023 | +4.3% | -1.4% | -0.6% | |
| Q1 2023 | +1.2% | -5.3% | +36.0% | |
| Q4 2022 | -1.5% | +3.3% | -9.1% | |
| Q3 2022 | +3.8% | +1.0% | -3.0% | |
| Q2 2022 | -5.6% | +0.8% | -3.5% | |
| Q1 2022 | +13.5% | +6.8% | +12.1% | |
| Q4 2021 | +8.8% | +3.0% | -8.6% | |
| Q3 2021 | -4.5% | -10.1% | -28.8% | |
| Q2 2021 | +7.8% | +3.8% | +8.0% | |
| Q1 2021 | +2.2% | +12.4% | +13.1% | |
| Q4 2020 | +9.5% | +8.4% | -13.9% | |
| Q3 2020 | — | — | — | |
| Q2 2020 | — | — | — | |
| Q1 2020 | — | — | — | |
| Q4 2019 | — | — | — | |
| Q3 2019 | — | — | — | |
| Q2 2019 | — | — | — | |
| Q1 2019 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro